United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

3:59pm EST
Change (% chg)

$0.05 (+0.55%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

European Regulatory Authority approves clinical investigator's request for compassionate use with Omeros Corp 's OMS721
Tuesday, 14 Apr 2015 07:00am EDT 

Omeros Corp:Says that presiding European regulatory authority has approved company's investigational product OMS721 for compassionate use.Says OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for treatment of thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome (aHUS).Says TMAs are family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in microcirculation of the body's organs, most commonly the kidney and brain.Two patients in compassionate-use study suffer from aHUS and were enrolled in first cohort of Phase 2 clinical trial.Based on improvements across markers of disease activity in that cohort, the investigator requested that Omeros continue to provide OMS721 so that the patients could extend their treatments.Following regulatory approval, Omeros was pleased to release shipment of OMS721 to continue treatment of these patients.  Full Article

Omeros Corp closes $84 mln public offering of common stock and pre-funded warrants
Tuesday, 3 Feb 2015 05:01pm EST 

Omeros Corp:Closed underwritten public offering that was priced and allocated to investors on Jan. 28.Relating to sale of 3,444,831 shares of common stock at price of $20.03 per share and 749,250 pre-funded warrants to purchase up to equal number of shares of common stock at price per warrant of $20.02, which was paid at closing.Pre-funded warrants have exercise price of $0.01 per share and will expire on Feb. 3, 2022.Gross proceeds from offering were about $84.0 mln, including about $15.0 mln from sale of pre-funded warrants.Closing also included sale of 449,325 shares of common stock sold pursuant to option allowing underwriters to purchase additional shares of common stock from Omeros, which the underwriters exercised in full.After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from transaction of about $79.1 mln.Cowen and Company, LLC acted as the sole book-running manager for offering.Wedbush PackGrow Life Sciences acted as co-lead manager.Needham & Company, LLC, Maxim Group LLC, WBB Securities LLC and MLV & Co. LLC acted as co-managers.  Full Article

BRIEF-Omeros Q3 loss per share $0.34

* Omeros Corporation reports third quarter 2016 financial results